# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001213900-25-033322
Filing Date
2025-04-18
Accepted
2025-04-18 15:05:14
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE ADDITIONAL MATERIALS | ea0237916-defa14a_orukathera.htm | DEFA14A | 17420
2 | GRAPHIC | image_001.jpg | GRAPHIC | 724128
3 | GRAPHIC | image_002.jpg | GRAPHIC | 513567
| Complete submission text file | 0001213900-25-033322.txt |  | 1723479

Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 25850272
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)